lifestyle.onebyfourstudio.com

Author: Pharvaris N.V.

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

April 20, 2026
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

April 2, 2026
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology

March 20, 2026
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

March 11, 2026
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026

March 2, 2026
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

February 11, 2026